OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 19 of 33

20 Anti-obesity Pharmacotherapy Eating Disorders and Miscellaneous Agent/Dose Description Main Side Effects/ Adverse Reactions Sympathomimetic Amines Phentermine, diethylpropion, phendimetrazine, benzphetamine Decrease appetite • DEA IV for phentermine and diethylpropion • DEA III for phendimetrazine and benzphetamine • Palpitations • Tachycardia • Increased blood pressure • Overstimulation • Tremor • Dizziness • Insomnia • Dysphoria • Headache • Dryness of mouth • Dysgeusia • Diarrhea and/or constipation • Restlessness (cont'd)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024